S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation

Arecor Therapeutics (AREC) Competitors

GBX 137.50
0.00 (0.00%)
(As of 03/1/2024 ET)

AREC vs. TRX, DEST, POLB, HEMO, C4XD, OBD, SAR, OBI, OPTI, and SBTX

Should you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include Tissue Regenix Group (TRX), Destiny Pharma (DEST), Poolbeg Pharma (POLB), Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), Oxford BioDynamics (OBD), Sareum (SAR), Ondine Biomedical (OBI), OptiBiotix Health (OPTI), and SkinBioTherapeutics (SBTX). These companies are all part of the "biotechnology" industry.

Arecor Therapeutics vs.

Tissue Regenix Group (LON:TRX) and Arecor Therapeutics (LON:AREC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.

50.1% of Tissue Regenix Group shares are held by institutional investors. Comparatively, 54.2% of Arecor Therapeutics shares are held by institutional investors. 49.9% of Tissue Regenix Group shares are held by company insiders. Comparatively, 31.3% of Arecor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tissue Regenix Group has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Arecor Therapeutics has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

In the previous week, Tissue Regenix Group had 1 more articles in the media than Arecor Therapeutics. MarketBeat recorded 1 mentions for Tissue Regenix Group and 0 mentions for Arecor Therapeutics. Arecor Therapeutics' average media sentiment score of 0.67 beat Tissue Regenix Group's score of 0.00 indicating that Tissue Regenix Group is being referred to more favorably in the media.

Company Overall Sentiment
Tissue Regenix Group Positive
Arecor Therapeutics Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tissue Regenix Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Arecor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Tissue Regenix Group has higher revenue and earnings than Arecor Therapeutics. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Arecor Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tissue Regenix Group£26.74M1.81-£1.98M-£0.02-3,425.00
Arecor Therapeutics£3.38M12.46-£9.42M-£0.31-443.55

Tissue Regenix Group has a net margin of -7.42% compared to Tissue Regenix Group's net margin of -278.81%. Arecor Therapeutics' return on equity of -6.15% beat Tissue Regenix Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tissue Regenix Group-7.42% -6.15% -1.39%
Arecor Therapeutics -278.81%-67.81%-34.01%

Tissue Regenix Group received 162 more outperform votes than Arecor Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Tissue Regenix GroupOutperform Votes
162
69.53%
Underperform Votes
71
30.47%
Arecor TherapeuticsN/AN/A

Summary

Tissue Regenix Group beats Arecor Therapeutics on 11 of the 14 factors compared between the two stocks.


Get Arecor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AREC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AREC vs. The Competition

MetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£42.12M£217.99M£5.19B£1.52B
Dividend YieldN/A3.47%2.82%11.57%
P/E Ratio-443.55215.13195.341,945.91
Price / Sales12.4626,303.713,036.00417,059.95
Price / Cash5.0711.1398.8332.66
Price / Book3.206.024.522.66
Net Income-£9.42M-£16.20M£114.88M£174.10M
7 Day Performance-8.33%-0.33%5.68%0.33%
1 Month Performance-16.92%4.52%11.22%5.29%
1 Year Performance-42.73%72.64%14.02%13.79%

Arecor Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRX
Tissue Regenix Group
0 of 5 stars
GBX 63
flat
N/A+10,740.0%£44.46M£26.74M-3,150.0085News Coverage
High Trading Volume
DEST
Destiny Pharma
0 of 5 stars
GBX 43
+3.6%
N/A-4.5%£40.97M£135,028.00-537.5024
POLB
Poolbeg Pharma
0 of 5 stars
GBX 10.90
-5.2%
N/A+9.3%£54.50MN/A-1,090.0012
HEMO
Hemogenyx Pharmaceuticals
0 of 5 stars
GBX 3.13
-6.8%
N/A-12.1%£36.93MN/A-313.0014Gap Down
C4XD
C4X Discovery
0 of 5 stars
GBX 12.50
-3.8%
N/A-32.4%£31.53M£1.71M-312.5049News Coverage
Gap Down
OBD
Oxford BioDynamics
0 of 5 stars
GBX 14
+4.5%
N/A-34.8%£28.32M£176,000.00-200.0043Gap Up
SAR
Sareum
1.3202 of 5 stars
GBX 40
+33.3%
GBX 304
+660.0%
-64.7%£28.10M£47,204.00-800.005Gap Up
High Trading Volume
OBI
Ondine Biomedical
0 of 5 stars
GBX 10
-2.4%
N/A-45.1%£22.68M£856,000.00-166.67N/A
OPTI
OptiBiotix Health
0 of 5 stars
GBX 22
-8.3%
N/A+120.0%£20.06M£1.26M-146.679Gap Down
High Trading Volume
SBTX
SkinBioTherapeutics
0 of 5 stars
GBX 10.50
+1.0%
N/A-52.4%£20.04M£21,949.00-525.0011Gap Down

Related Companies and Tools

This page (LON:AREC) was last updated on 3/2/2024 by MarketBeat.com Staff